Claim · model-written summary
The ethyl acetate extract had an alpha-glucosidase inhibition IC50 of 23.04 g/ml.
- Taxon
- Terminalia bellerica
Terminalia belliricat0 - Treatment
- ethyl acetate extracte5
- Outcome
- α-glucoside inhibition IC50e5
- Value
- 23.04e5
Not reportedMaterialGeneCompoundOrgan / stageInteractorInteractor roleSecond interactorSecond interactor roleComparatorSettingDirectionQualifier
Organisms pictured · Representative pictures of the matched species, not figures from the paper.
Verbatim
t0“Terminalia bellerica Seed Extracts in Various Solvent Polarities”
e5“The ethyl acetate extract has α-glucoside inhibition IC50 of 23.04 g/ml and α-amylase inhibition IC50 of 25.35 g/ml”
Title
Atmira Sariwati; Fita Sari; Venty Suryanti; et al. HAYATI Journal of Biosciences 2024. doi:10.4308/hjb.31.5.854-866
Other claims from this paper (10)
- Observation Phenol concentration of Terminalia bellerica seed extracts ranged between 23.45 and 160.41 mg GAE/g across solvents.
- Observation Flavonoid concentration of Terminalia bellerica seed extracts ranged from 88.52 to 7.12 mg QE/g across solvents.
- Observation Tannic acid content of Terminalia bellerica seed extracts spanned from 0.78 to 5.32 mg TAE/g across solvents.
- Intervention effect The ethyl acetate extract of Terminalia bellerica seed showed the most significant level of antioxidant activity among the solvent extracts.
- Observation The ethyl acetate extract had a DPPH IC50 of 28.17 g/ml.
- Observation The ethyl acetate extract had an ABTS IC50 of 22.22 g/ml.
- Observation The methanol extract showed antibacterial activity against Staphylococcus aureus (23 mm inhibition zone).
- Observation The methanol extract showed antifungal activity (21 mm inhibition zone) against an organism not named in the abstract text.
- Observation The ethyl acetate extract had an alpha-amylase inhibition IC50 of 25.35 g/ml.
- Observation Terminalia bellerica seed secondary metabolites show promise as lead chemicals for potent medications.